JP2017502003A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502003A5
JP2017502003A5 JP2016538037A JP2016538037A JP2017502003A5 JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5 JP 2016538037 A JP2016538037 A JP 2016538037A JP 2016538037 A JP2016538037 A JP 2016538037A JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5
Authority
JP
Japan
Prior art keywords
phe
pro
tyr
aib
nal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016538037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502003A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077240 external-priority patent/WO2015086686A2/en
Publication of JP2017502003A publication Critical patent/JP2017502003A/ja
Publication of JP2017502003A5 publication Critical patent/JP2017502003A5/ja
Pending legal-status Critical Current

Links

JP2016538037A 2013-12-13 2014-12-10 プロテアーゼ耐性ペプチド Pending JP2017502003A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915662P 2013-12-13 2013-12-13
US61/915,662 2013-12-13
PCT/EP2014/077240 WO2015086686A2 (en) 2013-12-13 2014-12-10 Protease resistant peptides

Publications (2)

Publication Number Publication Date
JP2017502003A JP2017502003A (ja) 2017-01-19
JP2017502003A5 true JP2017502003A5 (enExample) 2017-12-28

Family

ID=52021207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538037A Pending JP2017502003A (ja) 2013-12-13 2014-12-10 プロテアーゼ耐性ペプチド

Country Status (11)

Country Link
US (1) US20160318987A1 (enExample)
EP (2) EP3415526A1 (enExample)
JP (1) JP2017502003A (enExample)
KR (1) KR20160098406A (enExample)
CN (1) CN105849123A (enExample)
AU (1) AU2014363547A1 (enExample)
BR (1) BR112016013157A2 (enExample)
CA (1) CA2933405A1 (enExample)
MX (1) MX2016007407A (enExample)
SG (1) SG10201805039UA (enExample)
WO (1) WO2015086686A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
CA3003465A1 (en) 2015-10-28 2017-05-04 Krishna Kumar Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
CA3025592A1 (en) 2016-06-09 2017-12-14 Medimmune Limited Protease-resistant mono-lipidated peptides
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
PE20211417A1 (es) 2018-04-05 2021-08-02 Sun Pharmaceutical Ind Ltd Analogos novedosos de glp-1
CN115348876A (zh) * 2020-03-31 2022-11-15 安塔罗斯医疗公司 用于成像和治疗目的的包含螯合部分的选择性gip受体激动剂
CN116685599A (zh) * 2020-12-16 2023-09-01 免疫医疗有限公司 多肽及其用途
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG125915A1 (en) * 1998-12-07 2006-10-30 Sod Conseils Rech Applic Analogues of glp-1
PT1987052E (pt) * 2006-02-08 2011-07-25 Lonza Ag Síntese de péptidos tipo glucagina
EP2021014A1 (en) * 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
WO2008023050A1 (en) * 2006-08-25 2008-02-28 Novo Nordisk A/S Acylated exendin-4 compounds
CA2707448C (en) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
EP2110380B1 (en) * 2008-04-18 2010-11-10 F. Hoffmann-La Roche AG Alpha-N-methylation of amino acids
WO2011048614A2 (en) * 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
US20130143800A1 (en) * 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
WO2014088631A1 (en) * 2012-12-06 2014-06-12 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same

Similar Documents

Publication Publication Date Title
JP2017502003A5 (enExample)
AR096162A1 (es) Péptidos terapéuticos
TWI455721B (zh) 癌疫苗組合物
NZ600732A (en) Oxyntomodulin peptide analogue
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
MX2019001925A (es) Proteina de fusion del factor viii de la coagulacion sanguinea humana altamente glicosilada y metodo de fabricacion y aplicacion del mismo.
PE20121393A1 (es) Analogo peptidico de oxintomodulina
TW201613958A (en) MIC-1 fusion proteins and uses thereof
WO2015188132A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
JP2017535527A5 (enExample)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
RU2011134596A (ru) Аналоги оксинтомодулина
JP2017522362A5 (enExample)
NZ708990A (en) Method for activating helper t cell
MX2024006356A (es) Metodos para predecir la utilidad de modificaciones de aminoacidos especificas de una enfermedad para inmunoterapia
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
AR096927A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
MX2014008028A (es) Proteina de fusion anticancerigena.
JP2019525753A5 (enExample)
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
SA521421371B1 (ar) لقاحات الببتيد
WO2012174397A3 (en) Anti-inflammatory pharmaceutical products
MX337756B (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.